Status:
COMPLETED
Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Peritonitis
Eligibility:
All Genders
18+ years
Brief Summary
When there is infection in the intra-abdominal area, bacteria secrete toxins that are absorbed by the peritoneum. These toxins then bind to lipoproteins (which carry cholesterol in the blood) and are ...
Eligibility Criteria
Inclusion
- person who has given oral consent (patient or family member)
- pre-operative SEPSIS criteria (qSOFA \>=2) or vasopressor or mechanical ventilation treatment
- admitted to the operating room for suspected generalized secondary peritonitis
Exclusion
- person not affiliated to national health insurance
- person under legal protection (curatorship, guardianship)
- person under court order
- pregnant, parturient or breastfeeding woman
- minor
- immunosuppression (HIV infection, corticosteroid treatment \> 0.15 mg/kg/day prednisolone equivalent \> 2 weeks, immunosuppressive treatment, primary cellular immune deficiency)
- decision to limit or stop therapy
Key Trial Info
Start Date :
December 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 27 2022
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04126577
Start Date
December 19 2019
End Date
October 27 2022
Last Update
August 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourogne
Dijon, France, 21000